SCHEMBL34468431

SCHEMBL34468431

C[C@H](O)c1cc(F)c(N2CCN(C(=O)OCc3ccccc3)CC2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.50
▸ ALDH1A1 P00352 6/20 0.50
▸ ALOX15 P16050 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 3/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ GRM5 P41594 1/20 0.45
▸ HDAC1 Q13547 2/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ DPP4 P27487 1/20 0.44
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ TMEM97 Q5BJF2 2/20 0.43
▸ SIGMAR1 Q99720 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34468403 0.90 MAPT (0.48) MAPTALDH1A1ALOX15HSD17B10HPGD
SCHEMBL34468432 0.84 L3MBTL1 (0.53) MAPTALDH1A1ALOX15HSD17B10HPGD
SCHEMBL34468351 0.83 MAPT (0.51) MAPTALDH1A1ALOX15HSD17B10HPGD
SCHEMBL34468439 0.81 FNTA (0.51) MAPTALDH1A1ALOX15HSD17B10HPGD
SCHEMBL12073842 0.80 MAPT (0.56) MAPTALDH1A1ALOX15HSD17B10HPGD
SCHEMBL34468455 0.79 FNTA (0.43) MAPTALDH1A1HSD17B10NPSR1LMNA
SCHEMBL20521279 0.77 MAPT (0.58) MAPTALDH1A1ALOX15HSD17B10HPGD
Hydrochloric Acid SCHEMBL23141825 0.77 MAPT (0.53) MAPTALDH1A1ALOX15HSD17B10HPGD
Hydrochloric Acid SCHEMBL30718967 0.77 MAPT (0.53) MAPTALDH1A1ALOX15HSD17B10HPGD
Hydrochloric Acid SCHEMBL23141822 0.77 MAPT (0.53) MAPTALDH1A1ALOX15HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115199-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2026-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115199-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 MAPT 4449/4885ALDH1A1 313/4885ALOX15 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback